Abstract
Epidermal Growth Factor Receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) patients failing first-line (1L) EGFR- tyrosine kinase inhibitors (TKI) can benefit from subsequent targeted therapies. However, the real world data on the testing patterns and subsequent treatment patterns among patients failing 1L EGFR-TKI are lacking.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have